Skip to main content
Astria Therapeutics, Inc. logo

Astria Therapeutics, Inc. — Investor Relations & Filings

Ticker · ATXS ISIN · US04635X1028 US Manufacturing
Filings indexed 602 across all filing types
Latest filing 2026-02-17 Major Shareholding Noti…
Country US United States of America
Listing US ATXS

About Astria Therapeutics, Inc.

https://astriatx.com/

Astria Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for allergic and immunologic diseases. The company's mission is to provide life-changing treatments to patients and their families. Its lead product candidate, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein being developed as a potential long-acting, preventative treatment for Hereditary Angioedema (HAE). The company has reported positive initial proof-of-concept results from its ALPHA-STAR Phase 1b/2 clinical trial for STAR-0215. Astria Therapeutics is guided by patient needs to develop differentiated therapeutics that address significant unmet medical needs.

Recent filings

Filing Released Lang Actions
SCHEDULE 13G/A Filing
Major Shareholding Notification
2026-02-17 English
SCHEDULE 13G/A Filing
Major Shareholding Notification
2026-02-12 English
SCHEDULE 13D/A - Astria Therapeutics, Inc. (0001454789) (Subject)
Major Shareholding Notification
2026-02-09 English
SCHEDULE 13D/A Filing
Major Shareholding Notification
2026-01-28 English
4 - ASTRIA THERAPEUTICS, INC. (0001454789) (Filer)
Director's Dealing
2026-01-23 English
25-NSE Filing
Delisting Announcement
2026-01-23 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.